O7125
L-Ornithine L-aspartate salt
≥98% (TLC)
Sinônimo(s):
(S)-2,5-Diaminopentanoic acid L-aspartate salt
Faça login para ver os preços organizacionais e de contrato.
Selecione um tamanho
Alterar visualização
| Tamanho da embalagem | SKU | Disponibilidade | Preço |
|---|---|---|---|
| 25 g | Verificar disponibilidade no carrinho | R$ 1.001,00 |
Sobre este item
Fórmula empírica (Notação de Hill):
C9H19N3O6
Número CAS:
Peso molecular:
265.26
NACRES:
NA.26
PubChem Substance ID:
UNSPSC Code:
12352209
EC Number:
221-772-7
MDL number:
Assistência Técnica
Precisa de ajuda? Nossa equipe de cientistas experientes está à sua disposição.
Estamos aqui para ajudarNome do produto
L-Ornithine L-aspartate salt, powder
assay
≥98% (TLC)
Quality Level
form
powder
color
white to off-white
storage temp.
2-8°C
SMILES string
NCCC[C@H](N)C(O)=O.N[C@@H](CC(O)=O)C(O)=O
InChI
1S/C5H12N2O2.C4H7NO4/c6-3-1-2-4(7)5(8)9;5-2(4(8)9)1-3(6)7/h4H,1-3,6-7H2,(H,8,9);2H,1,5H2,(H,6,7)(H,8,9)/t4-;2-/m00/s1
InChI key
IXUZXIMQZIMPSQ-ZBRNBAAYSA-N
Biochem/physiol Actions
L-Ornithine L-aspartate is a metabolite of arginine degradation by arginase. It has been shown to reduce blood ammonia concentrations by increasing ammoniadetoxification in the muscle and reducing the severity of hepatic encephalopathy in cirrhosis.
Other Notes
Product of arginine degradation by arginase
1 of 1
Este Item | |||
|---|---|---|---|
| form powder | form powder | form powder | form powder |
| assay ≥98% (TLC) | assay ≥99% | assay ≥99% | assay ≥99.0% (AT) |
| storage temp. 2-8°C | storage temp. - | storage temp. - | storage temp. - |
| color white to off-white | color white | color white | color - |
| Quality Level 200 | Quality Level 200 | Quality Level 200 | Quality Level 100 |
Classe de armazenamento
11 - Combustible Solids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
Escolha uma das versões mais recentes:
Já possui este produto?
Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.
Qian Jiang et al.
Journal of gastroenterology and hepatology, 24(1), 9-14 (2008-10-01)
Hepatic encephalopathy continues to be a major clinical problem and the current decade has not witnessed major therapeutic breakthroughs in this area. L-ornithine-l-aspartate (LOLA) is not frequently used as there are still some reservations about its benefits. The present study
Bin Zhang et al.
Bioresource technology, 284, 204-213 (2019-04-03)
l-ornithine, an important amino acid, is widely used in food and medicine industries. l-ornithine production mainly relies on microbial fermentation, which may not meet the industrial requirement owing to the poor fermentation ability of available strains. Herein, mscCG2 deletion, CgS9114_12202
Vibhu Vibhas Mittal et al.
European journal of gastroenterology & hepatology, 23(8), 725-732 (2011-06-08)
Minimal hepatic encephalopathy (MHE) impairs daily functioning and health-related quality of life (HRQoL). The modalities of treatment of MHE have not been adequately studied. To compare lactulose, probiotics, and L-ornithine L-aspartate (LOLA) in treatment of MHE and effect on HRQoL
Número de item de comércio global
| SKU | GTIN |
|---|---|
| O7125-25G | 04061834248392 |
| O7125-100G | 04061834248385 |